GlassScriptPhysician profile
Stephen Glen Markham
NPI 1790377331
$8,220.37
in general payments reported to CMS, 2019-2025
22 companies · $3,185 in 2025
The $3,185 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $923 · 2023: $2,585 · 2024: $1,528 · 2025: $3,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,798 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,797.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Education | $199.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,484.27 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,011.20 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $876.03 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $772.83 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $714.43 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $671.32 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $340.23 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $298.77 | 2022-2025 | Rexulti |
| Corium, LLC | $292.89 | 2022-2025 | Azstarys, Azstarys |
| Axsome Therapeutics, INC. | $248.55 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $199.25 | 2025 | Cobenfy |
| Novo Nordisk INC | $80.20 | 2023-2025 | Wegovy |
| Sage Therapeutics, LLC | $41.80 | 2025 | Zurzuvae |
| Tris Pharma INC | $33.34 | 2023 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $27.19 | 2023 | Spravato |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $24.17 | 2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $22.45 | 2022 | |
| Tempus Ai, INC | $19.30 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.28 | 2022 | |
| Glaxosmithkline, LLC. | $16.07 | 2023 | Trelegy Ellipta |
| Owp Pharmaceuticals, INC. | $14.48 | 2022 | |
| Lilly USA, LLC | $14.32 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Markham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.